Immune Checkpoint Dysregulation in Inflammatory Neuropathies: An Exploratory Study
Аннотация
ABSTRACT Introduction/Aims Inflammatory neuropathies (IN), such as Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), are characterized by peripheral nerve injury driven by immune activation, although the precise mechanisms remain unknown. Dysregulated immune checkpoint molecules (ICMs) are known to trigger autoimmunity and inflammation; however, the role of ICMs is not well elucidated in IN. We investigated the gene expression levels of ICMs, such as programmed cell death protein‐1 (PD‐1) and cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4), as well as their respective ligands (CD274, and CD86/CD80) in IN. Methods This case–control, cross‐sectional, hospital‐based study included 67 patients with IN (GBS = 47, CIDP = 20) and equal number of healthy controls. Gene expression levels of PDCD1 , CD274 , CTLA4 , CD86 , and CD80 were quantified using ddPCR and correlated with the clinical and electrophysiological parameters. Results PDCD1 , CTLA4 , CD274 , and CD86 gene expression levels were significantly higher in IN than in healthy controls ( p = 0.001, 0.017, 0.001, and 0.006, respectively). In GBS, PDCD1 and CD274 expression levels were significantly increased compared with controls ( p = 0.001 and 0.003, respectively), whereas in CIDP, the expression levels of CTLA4 , CD274 , CD86 , and CD80 were higher than in controls ( p = 0.050, 0.033, 0.003, and 0.016, respectively). CTLA4 , CD86 , and CD80 expression levels were greater in CIDP than in GBS ( p = 0.049, 0.001, and 0.014, respectively). Discussion This study demonstrates differential expression of ICMs in GBS and CIDP. The immune checkpoint pathways may play a crucial role in the pathogenesis of inflammatory neuropathies, which warrants further exploration in larger cohorts.